The Committee for Medicinal products for Human Use (CHMP) decided that Osigraft’ s benefits are greater than its risks for the treatment of nonunion of tibia of at least nine month duration, secondary to trauma, in skeletally mature patients, where previous treatment with autograft has failed or use of autograft is unfeasible.